MAp44 Polypeptide Constructs for Targeted Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for complement-mediated diseases, such as arthritis, do not effectively target the lectin pathway, which plays a crucial role in inflammatory processes, leading to ongoing tissue damage and inflammation.
Innovation Solution
Administration of MAp44 polypeptides or fragments linked to a targeting moiety, such as antibodies, to specifically inhibit complement activation at sites of tissue injury, thereby reducing inflammation and tissue damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for complement-mediated diseases are used, then general complement inhibition is achieved, but the lectin pathway is not effectively targeted, leading to ongoing tissue damage and inflammation
Solution Approach 1:
The patent applies local quality by creating MAp44 polypeptides with specific targeting moieties that direct the therapeutic agent to specific tissues and sites of inflammation. This allows the treatment to selectively inhibit complement activation where it is most harmful (at sites of tissue injury) while preserving complement function in other areas, thereby effectively targeting the lectin pathway where it is needed most to prevent tissue damage and inflammation
Solution Approach 2:
The patent uses MAp44 polypeptides as intermediary molecules that bridge the gap between natural antibodies and the complement system. These polypeptides contain targeting moieties that bind to specific antigens and Fc regions that interact with complement components, thereby mediating selective inhibition of complement activation through the lectin pathway while avoiding direct contact between antibodies and complement, which resolves the contradiction by providing targeted intervention
2Object-affected harmful factors
If MAp44 polypeptides linked to targeting moieties are administered, then specific inhibition of complement activation at sites of tissue injury is achieved, but the complexity of the treatment increases
Solution Approach 1:
The patent applies segmentation by dividing the MAp44 polypeptide into distinct functional modules: targeting moieties (such as antibody fragments or ligands) that recognize specific antigens at injury sites, and complement-inhibiting domains (such as C1q binding domains or C4b binding domains) that prevent complement activation. This modular structure allows each segment to perform its specific function independently while working together to achieve targeted complement inhibition, managing complexity through functional decomposition
Solution Approach 2:
The patent employs universality by designing MAp44 polypeptides that can perform multiple functions within a single molecule: antigen binding, complement component binding, and complement activation inhibition. This multi-functionality reduces the need for multiple separate therapeutic agents and simplifies the overall treatment structure while maintaining the ability to specifically inhibit complement activation at tissue injury sites
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of MAp44 constructs significantly attenuates arthritis by reducing complement activity, leading to decreased inflammation and tissue damage, as demonstrated in mouse models of collagen antibody-induced arthritis.
Implementation Method 1
MAp44, which is present in low levels in serum compared to other MASP proteins such as MASP-1 and MASP-3, functions as a local lectin pathway-specific complement inhibitor
Implementation Method 2
Administration of MAp44 polypeptides or fragments linked to a targeting moiety, such as antibodies, to specifically inhibit complement activation at sites of tissue injury
Data Source
AI summary
The present invention provides delivery methods and constructs for treating inflammatory diseases in an individual. The targeted delivery approach utilizes an antibody that recognizes an epitope found to be present at sites of inflammation. The antibody is used to deliver a MAp44 polypeptide or fragment thereof to sites of inflammation, where it inhibits the lectin pathway of complement activation.